Abstract
A 68-year-old woman diagnosed with erosive rheumatoid arthritis (RA) was treated with intramuscular methotrexate 15 mg weekly and oral prednisone 5 mg daily. A favorable outcome of 6 years was followed by RA flare and nephrotic syndrome (NS). Renal biopsy revealed non-amyloid light-chain deposition disease. Laboratory analysis and bone marrow biopsy excluded monoclonal protein and plasma cell dyscrasia. Addition of subcutaneous etanercept, 25 mg twice weekly allowed rapid control of both arthritis and NS. To date, after over 7-year follow-up, RA is in clinical remission, 24-h albuminuria is consistently below 0.5 g, and serum creatinine is 0.9 mg/dl.
This is a preview of subscription content, log in via an institution to check access.
References
Zhu L, Herrera FA, Murphy-Ulrich JE et al (1995) Pathogenesis of glomerulosclerosis in light chain deposition disease. Am J Pathol 147:375–385
Demeule B, Gurny R, Arvinte T (2006) Renal deposition of immunoglobulin aggregates. Eur J Pharm Biopharm 62:121–130
Heilman RL, Velosa JA, Holley KE et al (1992) Long-term follow-up and response to chemotherapy in patients with light-chain deposition disease. Am J Kidney Dis 20:34–41
Davis DP, Gallo G, Vogen SM et al (2001) Both the Environment and somatic mutation govern the aggregation pathway of pathogenic immunoglobulin light chain. JMB 313:1021–1034
Keeling J, Herrera GA (2009) An in vitro model of light chain deposition disease. Kidney Int 75:634–645
Cheon H, Sun YK, Yu SJ et al (2004) Platelet-derived growth factor-AA increases IL-1beta and IL-8 expression and activates NF-kappaB in rheumatoid fibroblast-like synoviocytes. Scand J Immunol 60:455–462
Rioja I, Hughes FJ, Sharp CH et al (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients. CXCL13, CCL23, transforming growth factor a, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum 58:2357–2367
Midwood K, Sacre S, Piccinini AM et al (2009) Tenascin-C is an endogenous activator of toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15:774–780
Valesini G, Montecucco C, Cutolo M (2006) Recommendations for the use of biologic (TNF-alpha blocking) agents in the treatment of rheumatoid arthritis in Italy. Clin Exp Rheumatol 24:413–423
Staroslawska E, Czarnocki KJ, Koziol-Montewka M et al (2008) Effect of infliximab on the levels of TNF-alpha and TGF-beta in the whole blood cultures of irradiated patients. Folia Histochem Cytobiol 46:291–297
Kallimanis PG, Xenos K, Markantonis SL et al (2009) Serum levels of transforming growth factor-beta1 in patients with mild psoriasis vulgaris and effect of treatment with biological drugs. Clin Exp Dermatol 34:582–586
Wollin M, Abele S, Bruns H et al (2009) Inhibition of TNF-alpha reduces transplant arteriosclerosis in a murine aortic transplant model. Transpl Int 22:342–349
Drewe E, McDermott EM, Powell RJ (2000) Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome. N Engl J Med 343:1044–1045
Pozzi C, Locatelli F (2002) Kidney and liver involvement in monoclonal light chain disorders. Semin Nephrol 22:319–330
van der Heijde DM, van’t Hof MA, van Riel PL et al (1992) Validity of single variables and composite indices for measuring disease activity in rheumatoid arthritis. Ann Rheum Dis 51:177–181
Dhodapkar MV, Merlini G, Solomon A (1997) Biology and therapy of immunoglobulin deposition disease. Hematol Oncol Clin North Am 11:89–110
Masai R, Wakui H, Togashi M et al (2009) Clinicopathological features and prognosis in immunoglobulin light and heavy chain deposition disease. Clin Nephrol 71:9–20
Lorenz EC, Gertz MA, Fervenza FC et al (2008) Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transpl 23:2052–2057
Short AK, O’Donoghue DJ, Riad HN et al (2001) Recurrence of light chain nephropathy in a renal allograft. A case report and review of the literature. Am J Nephrol 21:237–240
Caporali R, Caprioli M, Bobbio-Pallavicini F et al (2009) Long term treatment of rheumatoid arthritis with rituximab. Autoimmun Rev 8:591–594
van der Heijden JW, Oerlemans R, Lems WF et al (2009) The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 27:92–98
Kuypers DR, Lerut E, Claes K et al (2007) Recurrence of lightchain deposit disease after renal allograft transplantation: potential role of rituximab? Transpl Int 20:381–385
Kastritis E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA (2009) Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 94:300–302
Conflict of interest statement
The authors declare the lack of any conflict of interest knowing that false declaration is punished under law.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cavagna, L., Sepe, V., Bobbio-Pallavicini, F. et al. Rheumatoid arthritis and renal light-chain deposition disease: long-term effectiveness of TNF-α blockade with etanercept. Int Urol Nephrol 43, 909–912 (2011). https://doi.org/10.1007/s11255-010-9788-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-010-9788-6